By Fineline Cube Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that China’s National Medical Products Administration (NMPA) has approved its Phase II clinical trial application for BA1106, an investigational anti-CD25 monoclonal antibody, in combination with BA1104 (the company’s proprietary PD-1 inhibitor) for the first- and second-line treatment of non-small cell lung cancer (NSCLC). BA1106 represents China’s first non-IL-2-blocking innovative anti-CD25 antibody to advance into clinical development for solid tumors.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | National Medical Products Administration (NMPA) |
| Approval Type | Phase II Clinical Trial Application |
| Combination Therapy | BA1106 (anti-CD25 mAb) + BA1104 (PD-1 inhibitor) |
| Indication | First- and second-line treatment of NSCLC |
| Patient Population | Driver-gene-negative NSCLC subjects |
| Approval Date | 2 July 2026 |
Drug Profile & Innovation
- BA1106: Anti-CD25 monoclonal antibody targeting interleukin-2 receptor alpha subunit (IL-2Rα)
- Key Differentiation: Non-IL-2-blocking mechanism – first of its kind in China for solid tumor applications
- BA1104: Proprietary PD-1 inhibitor (nivolumab biosimilar or derivative)
- Therapeutic Rationale: Dual immunotherapy approach combining T-regulatory cell modulation with PD-1 pathway inhibition
- Innovation Status: First Chinese-developed anti-CD25 antibody with non-IL-2-blocking properties in clinical trials
Clinical Trial Design
| Parameter | Specification |
|---|---|
| Study Design | Multicenter, single-arm, open-label |
| Phase | Phase II |
| Primary Objectives | Evaluate efficacy, safety, and pharmacokinetic (PK) profiles |
| Target Population | Subjects with driver-gene-negative NSCLC |
| Treatment Lines | First- and second-line settings |
| Combination Regimen | BA1106 + BA1104 dual immunotherapy |
Strategic Significance & Market Context
| Aspect | Details |
|---|---|
| NSCLC Market Opportunity | Largest lung cancer segment representing ~85% of cases; significant unmet need in driver-gene-negative population |
| Immunotherapy Landscape | PD-1 inhibitors established as standard of care; combination approaches represent next frontier |
| CD25 Targeting Innovation | Novel approach to modulate tumor microenvironment by targeting regulatory T cells without blocking IL-2 signaling |
| China Biotech Leadership | Demonstrates advancement of domestic innovation beyond biosimilars to novel mechanism antibodies |
| Competitive Differentiation | Unique non-IL-2-blocking mechanism may offer improved safety profile compared to traditional anti-CD25 approaches |
Forward Outlook
The Phase II trial approval positions Shandong Boan Biotechnology to explore a potentially transformative combination immunotherapy approach for NSCLC patients who currently have limited treatment options. By combining its proprietary PD-1 inhibitor with a novel anti-CD25 antibody featuring a non-IL-2-blocking mechanism, the company aims to enhance anti-tumor immune responses while potentially avoiding the immunosuppressive effects associated with traditional IL-2 pathway blockade.
Success in this trial could establish BA1106 as a valuable addition to the immuno-oncology arsenal and validate CD25 as a viable target for solid tumor immunotherapy in the Chinese market. The company plans to leverage its established clinical development infrastructure and partnerships with leading oncology centers across China to accelerate patient enrollment and data generation.
This milestone reinforces Shandong Boan’s commitment to innovative antibody development and positions the company as a leader in next-generation immuno-oncology combinations within China’s rapidly evolving biopharmaceutical landscape.
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory approvals, and therapeutic potential. Actual results may differ due to risks including clinical trial outcomes, safety findings, competitive dynamics, and regulatory decisions.-Fineline Info & Tech